<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26303208</article-id><article-id pub-id-type="pmc">4548909</article-id><article-id pub-id-type="publisher-id">144</article-id><article-id pub-id-type="doi">10.1186/s12882-015-0144-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tai</surname><given-names>Davina J.</given-names></name><address><phone>(306) 934-3300</phone><email>davina_j_tai@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Leung</surname><given-names>Kelvin</given-names></name><address><email>kelvincwleung@gmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Ravani</surname><given-names>Pietro</given-names></name><address><email>pravani@ucalgary.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Quinn</surname><given-names>Robert R.</given-names></name><address><email>rob.quinn@albertahealthservices.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Scott-Douglas</surname><given-names>Nairne</given-names></name><address><email>nairne.scott-douglas@albertahealthservices.ca</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>MacRae</surname><given-names>Jennifer M.</given-names></name><address><phone>(403) 944-8168</phone><email>jennifer.macrae@albertahealthservices.ca</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><collab>For the Alberta Kidney Disease Network</collab></contrib><aff id="Aff1"><label/>Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan Canada </aff><aff id="Aff2"><label/>Department of Medicine, University of Calgary, Calgary, Alberta Canada </aff><aff id="Aff3"><label/>Department of Community Health Sciences, University of Calgary, Calgary, Alberta Canada </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>147</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Tai et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Unfractionated heparin is the most common anticoagulant used in haemodialysis (HD), although it has many potential adverse effects. Citrate dialysate (CD) has an anticoagulant effect which may allow reduction in cumulative heparin dose (CHD) compared to standard acetate dialysate (AD).</p></sec><sec><title>Methods</title><p>This double-blinded, randomised, cross-over trial of chronic haemodialysis patients determines if CD allows reduction in CHD during HD compared with AD. After enrolment, intradialytic heparin is minimised during a two-week run-in period using a standardised protocol based on a visual clotting score. Patients still requiring intradialytic heparin after the run-in period are randomised to two weeks of HD with AD followed by two weeks of CD (Sequence 1) or two weeks of HD with CD followed by two weeks of AD (Sequence 2). The primary outcome is the change in CHD with CD compared with AD. Secondary outcomes include metabolic and haemodynamic parameters, and dialysis adequacy.</p></sec><sec><title>Discussion</title><p>This randomised controlled trial will determine the impact of CD compared with AD on CHD during HD.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01466959">NCT01466959</ext-link></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Citrate dialysate</kwd><kwd>Hemodialysis</kwd><kwd>Haemodialysis</kwd><kwd>Unfractionated heparin</kwd><kwd>Anticoagulation</kwd><kwd>Randomised controlled trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>During haemodialysis (HD), blood is exposed to an extracorporeal circuit which activates thrombogenic pathways and clotting [<xref ref-type="bibr" rid="CR1">1</xref>]. Clotting in the dialysis circuit decreases HD efficiency, and increases nursing workload and costs [<xref ref-type="bibr" rid="CR2">2</xref>]. Even subclinical clotting of the dialysis circuit may reduce effective dialyser surface area and pore size, decreasing both small and middle solute clearance. Additionally, activation of the coagulation pathway in HD patients may be associated with increased inflammation and accelerated atherosclerosis [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>In North America, unfractionated heparin is the most common anticoagulant used to prevent clotting during HD [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Although effective and inexpensive, it has a narrow therapeutic window without adverse bleeding. Since heparin provides systemic anticoagulation, it is contraindicated in the setting of active bleeding, trauma, pericarditis, intracerebral haemorrhage, thrombocytopenia, coagulopathy, and peri-operative care [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Furthermore, heparin may lead to osteoporosis, dyslipidaemia, hyperkalaemia, and immune-mediated heparin-induced thrombocytopenia [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>An alternative to systemic heparin anticoagulation for HD is citrate dialysate (CD). CD contains a small amount of citric acid rather than acetic acid as the acidifying agent, at one-fifth the concentration of citric acid used for regional citrate anticoagulation. There are several observational studies [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>] and two randomised trials using CD in HD patients [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. These studies demonstrate that CD is associated with decreased clotting of the haemodialysis circuit [<xref ref-type="bibr" rid="CR17">17</xref>], decreased need for anticoagulation [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], increased dialyser reuse [<xref ref-type="bibr" rid="CR19">19</xref>], and increased small and middle solute clearance [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. These benefits are from an anticoagulation effect that is limited to the extracorporeal circuit without systemic coagulation activation [<xref ref-type="bibr" rid="CR28">28</xref>]. Other associated benefits of CD include decreased acidosis [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], decreased inflammation [<xref ref-type="bibr" rid="CR27">27</xref>], decreased oxidative stress [<xref ref-type="bibr" rid="CR25">25</xref>], improved anaemia [<xref ref-type="bibr" rid="CR22">22</xref>], improved nutrition [<xref ref-type="bibr" rid="CR22">22</xref>], and greater haemodynamic stability [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. CD is well tolerated with no unstable metabolic parameters and no documented adverse effects [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], even in paediatric patients with acute kidney injury [<xref ref-type="bibr" rid="CR32">32</xref>], in critically ill patients [<xref ref-type="bibr" rid="CR17">17</xref>], and patients with advanced liver failure [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>We describe our protocol for a six-week, double-blinded, randomised cross-over trial that investigates whether CD results in reduced cumulative heparin dose (CHD) compared to acetate dialysate (AD) in chronic HD patients. Secondary outcomes address safety concerns, and include metabolic and haemodynamic parameters, and dialysis adequacy.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study setting</title><p>This randomised crossover clinical trial is performed within three community HD units in Calgary, Alberta, Canada, where unfractionated heparin is used for standard intradialytic anticoagulation. All participants provide written informed consent. The study protocol is approved by the Conjoint Health Research Ethics Board at the University of Calgary, and is conducted in accordance with the Declaration of Helsinki (ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT01466959">NCT01466959</ext-link>).</p></sec><sec id="Sec4"><title>Study population</title><p>Eligible patients are&#x02009;&#x02265;&#x02009;18&#x000a0;years, and on outpatient conventional HD three times per week for at least three months. Exclusion criteria include: contraindication to heparin, heparin-free HD, known clotting disorder, warfarin therapy, dialysing with a dysfunctional central venous catheter (blood flow rate consistently&#x02009;&#x0003c;&#x02009;300&#x000a0;mL/min and/or frequent use of thrombolytic), vascular access dysfunction, planned vascular access conversion or procedure during the study period, use of high calcium dialysate, active medical issue, planned kidney transplant during the study period, planned conversion of dialysis modality (peritoneal dialysis, nocturnal dialysis) during the study period, or inability to provide informed consent. Patients with recent modifications to their erythropoiesis-stimulating agent dose are reviewed by the investigator for eligibility.</p></sec><sec id="Sec5"><title>Study protocol</title><p>After enrolment, each patient&#x02019;s dose of intradialytic heparin is minimised during a two-week run-in period (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) using study protocol (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) which is based on a standardised visual clotting score [<xref ref-type="bibr" rid="CR34">34</xref>]. The visual clotting score is quantified by inspecting the venous chamber and all four quadrants of the dialyser at the end of the HD session (0: clear dialyser/no clots; 1: few strands/small clots; 2: half clotted; 3: three-quarters clotted; 4: completely clotted, unable to return blood) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The heparin dose is reduced to reach a target visual clotting score of 2, then increased slightly and maintained, to achieve the lowest possible dose required to prevent clotting (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The CHD during the last HD session of the run-in period is considered to be the patient&#x02019;s baseline heparin dose. Patients still requiring intradialytic heparin after the two-week run-in period, and who still meet inclusion and exclusion criteria, are randomised to one of two treatment sequences (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). For sequence 1, patients undergo six HD sessions over two weeks with AD (control), followed by six HD sessions over two weeks with CD (intervention). For sequence 2, patients undergo six HD sessions over two weeks with CD (intervention), followed by two weeks of AD (control) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Patients begin each study phase (AD and CD) with their baseline intradialytic heparin dose, determined at the end of the run-in period. Nurses subsequently adjust intradialytic heparin dose per protocol (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) during each HD session of each study phase. At the end of the first study phase (two weeks), a 68-h washout period ensures no potential for a carry-over effect. After the wash-out period, patients cross-over to the other treatment for the next two weeks beginning again with their baseline heparin dose (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A two-week duration for each strategy is chosen to ensure adequate time to attain the minimum required heparin dose.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study Flow Diagram</p></caption><graphic xlink:href="12882_2015_144_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Visual Clotting Score and Heparin Protocol</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clotting Score</th><th>Dialyser/Venous Chamber Appearance (at the end of each HD session)</th><th>Heparin Dose Adjustment (for the next HD session)</th></tr></thead><tbody><tr><td>0</td><td>Clear</td><td>Decrease<sup>a</sup> boost by 200 units <italic>and</italic> decrease running dose by 200 units/h</td></tr><tr><td>1</td><td>Few strands/small clot</td><td>Decrease<sup>a</sup> boost by 200 units <italic>and</italic> decrease running dose by 200 units/h</td></tr><tr><td>2</td><td>&#x000bd; clotted</td><td>Increase boost by 200 units <italic>and</italic> increase running dose by 200 units/h and <italic>maintain</italic> this new heparin dose for the remainder of this study phase only.</td></tr><tr><td>3</td><td>&#x000be; clotted (able to return blood)</td><td>Increase boost by 300 units <italic>and</italic> increase running dose by 300 units/h</td></tr><tr><td>4</td><td>Completely clotted (unable to return blood)</td><td>Increase boost by 400 units <italic>and</italic> increase running dose by 400 units/h</td></tr></tbody></table><table-wrap-foot><p>
<italic>HD</italic> haemodialysis</p><p>NOTE</p><p>1) If there is unusually prolonged bleeding from vascular access sites post-HD, for the next HD session, decrease<sup>a</sup> heparin running dose by 200 units/h and turn heparin off 30&#x000a0;min earlier than usual</p><p>2) If there is a discrepancy in score between the dialyser and the venous chamber, the heparin dose adjustment is based on the dialyser clotting score</p><p>
<sup>a</sup>The minimum possible heparin boost and running dose are 500 units (boost) and 500 units/h. If the heparin dose is to be decreased to less than 500 units (boost and/or running dose) for the next HD session, discontinue the boost and/or the running dose</p></table-wrap-foot></table-wrap></p><p>Randomisation is determined by a computer generated random number list and concealed in sequentially numbered, opaque, sealed envelopes to ensure allocation concealment. Following informed consent and enrolment, the envelope containing allocation sequence is provided to the research coordinator who implements the sequence assignment according to protocol. The intervention and control dialysates, CD and AD, are packaged identically by the manufacturer (Chief Medical Supplies, Ltd., Calgary, Alberta, Canada) for blinding of investigators, patients, and health care staff. All data is confidential, and entered into electronic records by an independent data entry clerk who is blinded to patient allocation.</p><p>All study patients are dialysed using Gambro Phoenix&#x000ae; dialysis systems (Gambro-Hospal, Mirandola, Italy) at least three times per week. Each patient&#x02019;s target weight and dialysis prescription are optimised at the study start by the rounding nephrologist using clinical assessment. Standard dialysis prescriptions (blood flow rate 300&#x02013;450&#x000a0;mL/min, dialysate flow rate 500&#x000a0;mL/min, dialysate temperature 0.5&#x000a0;&#x000b0;C less than patient temperature, dialysate sodium 137&#x000a0;mmol/L) are maintained unless otherwise prescribed. Dialysers are high-flux, polysulfone (REXEED&#x02122;, Asahi Kasei Medical Co. Ltd., Tokyo, Japan). HD prescriptions, target weights, and antihypertensive medications are not changed during the study period. The intervention dialysate, CD, contains 2.4&#x000a0;mEq/L of citric acid (Citrasate&#x000ae;, Advanced Renal Technologies, Bellevue, WA), and the control dialysate, AD, contains 4&#x000a0;mmol/L of acetic acid.</p></sec><sec id="Sec6"><title>Study endpoints</title><p>Primary outcome measures are the absolute and percent change in CHD from baseline with CD compared with AD. CHD is defined as the total heparin received per dialysis session. Secondary outcomes are the effect of CD compared with AD on systemic anticoagulation (prothrombin time [PT]/international normalised ratio [INR], activated partial thromboplastin time [aPTT]), intradialytic metabolic parameters (serum total serum calcium, ionized calcium, magnesium, bicarbonate), anaemia, haemodynamic stability (blood pressure, heart rate, corrected QT interval, number of HD sessions complicated by intradialytic hypotension), dialysis adequacy (single pool Kt/V, urea reduction ratio, beta-2-microglobulin [B2M]), systematic inflammation (C-reactive protein [CRP]), bleeding time after HD, and bleeding events. Also, the visual clotting score and the dialyser fibre bundle volume (FBV) (as measured by the ultrasound dilution technique [<xref ref-type="bibr" rid="CR35">35</xref>]) are correlated. Lastly, the intra-rater and inter-rater reliability of the visual clotting score is assessed.</p></sec></sec><sec id="Sec7"><title>Data collection</title><sec id="Sec8"><title>Baseline characteristics</title><p>Baseline patient demographics (age, gender, HD vintage, race), comorbidities, cause of ESRD, labs, and HD prescription (dialyser, dialysate composition and temperature, blood and dialysate flow rates, target weight, anticoagulation) are extracted from HD charts and the Southern Alberta Renal Program database [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec9"><title>Cumulative heparin dose</title><p>The CHD is calculated per HD session, and determined from HD run sheets. Specifically, CHD is the initial heparin bolus, plus the hourly heparin infusion rate multiplied by the time on HD during which heparin is infused, per session, in heparin units. For the primary outcome, the CHD for the last two HD runs of each study phase are recorded, averaged, and used to calculate change from baseline CHD. The last two HD sessions of each phase is chosen to allow adequate time in each phase for heparin dose minimisation.</p></sec><sec id="Sec10"><title>Visual clotting score, inter-and intra-rater reliability</title><p>The clotting score is a visual grade of dialyser and venous chamber clotting (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). To ensure consistency, scoring of dialyser/venous chamber clotting for heparin dose adjustments are performed at the end of each HD session by a single, trained research nurse. A second HD nurse independently and blindly scores the dialyser/venous chamber appearance; this second clotting score is recorded to assess inter-rater reliability, but is not used to adjust the heparin dose per protocol. To assess for intra-rater reliability, at the end of each HD session during the run-in phase, the dialyser quadrants are captured in four photographs by the same trained research nurse, using a digital camera on a tripod, with standardised lighting, at a standardised distance and height from the dialyser. The dialyser is rotated by 90&#x000b0; for each of the four photographs, to visually capture the full circumferential view of the dialyser. The photographs are re-presented in a blinded fashion to the same research nurse at a later date to be re-scored.</p></sec><sec id="Sec11"><title>Metabolic, anticoagulation, and inflammatory parameters</title><p>Serum total calcium, ionized calcium, albumin, magnesium, bicarbonate, haemoglobin, urea, PT/INR, aPTT, B2M, and CRP are collected at the beginning of the first HD session of the study (whether randomised to Sequence 1 or 2), and drawn again both pre and post HD for the last HD sessions of each study phase. Ionized calcium is drawn pre and post HD during the first and last HD session in each study phase.</p></sec><sec id="Sec12"><title>Haemodynamic parameters</title><p>Blood pressure and heart rate are measured and recorded by HD nurses pre and post HD, and every 30&#x000a0;min during HD. The number of HD sessions complicated by intradialytic hypotension (IDH) during each study phase is recorded. IDH is defined as a drop in the systolic blood pressure (SBP) by&#x02009;&#x02265;&#x02009;20&#x000a0;mmHg to&#x02009;&#x0003c;&#x02009;100&#x000a0;mmHg with patient symptoms or nursing/physician intervention. If the patient&#x02019;s pre-HD SBP is&#x02009;&#x0003c;&#x02009;100&#x000a0;mmHg, then IDH is defined as a drop in SBP&#x02009;&#x02265;&#x02009;10&#x000a0;mmHg with patient symptoms or nursing/physician intervention. An electrocardiogram is performed at baseline (after the run-in phase), as well as pre and post HD during the last HD session in each two week study phase.</p></sec><sec id="Sec13"><title>Dialysis adequacy</title><p>Single pool Kt/V is determined for each HD session using Diascan&#x000ae; (Hospal-Gambro, Mirandola, Italy), which measures the dialysance of sodium through the dialyser membrane corrected for recirculation and ultrafiltration [<xref ref-type="bibr" rid="CR37">37</xref>], and which is a validated method for measuring urea clearance [<xref ref-type="bibr" rid="CR38">38</xref>]. In addition, the urea reduction ratio is calculated for the last HD session of each study phase using the equation ((urea pre&#x02014;urea post)/urea pre).</p></sec><sec id="Sec14"><title>Bleeding time and bleeding events</title><p>For the last two HD sessions of each study phase, the bleeding time post-HD is recorded and averaged in patients who have a fistula or graft as their vascular access. Bleeding events are documented and classified into: 1) major bleeding (fatal bleeding, overt bleeding associated with a haemoglobin drop&#x02009;&#x02265;&#x02009;20&#x000a0;g/L and/or transfusion with 2 units of red blood cells, retroperitoneal/intracranial/intraspinal/intra-ocular/pericardial/non-traumatic intra-articular bleeding), 2) clinically important non-major bleeding (clinically overt bleeding requiring hospital admission or visit to a medical facility or leading to intervention), and 3) minor bleeding (any bleeding episode not meeting criteria for the preceding bleeding categories).</p></sec><sec id="Sec15"><title>Fibre bundle volume</title><p>FBV is the space within the blood compartment of hollow fibre dialysers [<xref ref-type="bibr" rid="CR35">35</xref>]. Using the ultrasound dilution technique (Transonic&#x000ae; HD02 monitor, Transonic Systems Inc.&#x000ae;, Ithaca, NY, USA), dialyser FBV is measured twice (and the mean recorded) during both the first and last 30&#x000a0;min of the mid-week HD sessions throughout the entire study period (including the run-in phase). The change in FBV during HD represents the quantity of clot in the dialyser [<xref ref-type="bibr" rid="CR35">35</xref>] and is determined using the equation ((FBV pre&#x02014;FBV post)/FBV pre).</p></sec></sec><sec id="Sec16"><title>Sample size calculations</title><p>Previous studies have demonstrated that CHD is reduced by 30&#x000a0;% with the use of CD [<xref ref-type="bibr" rid="CR39">39</xref>]. Locally in Calgary, the mean CHD is 3000 units (standard deviation 900 units) per HD session in 85&#x000a0;% of HD patients. Based on this, and taking into account a 30&#x000a0;% dropout rate, we estimate that 20 patients are required to demonstrate a 30&#x000a0;% (1000 units) reduction in CHD with CD compared to AD (alpha 0.05, power 80&#x000a0;%). We use the method of Frison and Pocock for the ANCOVA model, and Rabe-Hesketh and Skrondal for the mixed linear model solution (StataCorp LP version SE 11.0, College Station, TX, USA).</p></sec><sec id="Sec17"><title>Statistical analysis</title><p>Baseline characteristics will be presented as means and 95&#x000a0;% confidence intervals (CIs) or medians and interquartile range (IQR) for continuous variables, and absolute and relative proportions for categorical variables. To determine the effect of CD compared with AD on reduction in CHD (the primary outcome) a random intercept linear mixed model will be used, with CD or AD as the main exposure, subjects as source of random effects, baseline heparin dose values as covariate (at least 2 of 3 measures from the first of two weeks of each period), and final heparin dose values as outcome (at least 2 of 3 measures of the second week of each period). This model takes into account the correlation of data caused by repeated measures for each subject given the crossover design of the study. Treatment, treatment period, and treatment sequence will be modelled as fixed effects. If there is no evidence of period or carry-over effects, all comparisons will be presented relative to AD, without the need for consideration of carry-over effects.</p></sec><sec id="Sec18" sec-type="discussion"><title>Discussion</title><p>CD has the potential to decrease intradialytic anticoagulation requirements, and improve patient outcomes. However, existing literature comparing CD to AD is limited. Most studies are small, observational in nature, and focus on dialysis adequacy, dialyser reuse/clotting, or metabolic/inflammatory/haemodynamic parameters [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Only two prospective randomised studies comparing CD to AD have been performed. One single-centre, unblinded crossover study randomised twenty-three maintenance HD patients to first receive CD without anticoagulation or AD with a Tinzaparin bolus [<xref ref-type="bibr" rid="CR29">29</xref>]. If the CD session revealed early clotting of the venous chamber or dialyser, a Tinzaparin bolus at half the usual dose could be given, and repeated once. During the HD sessions with CD, 50&#x000a0;% of patients did not require anticoagulation, 32&#x000a0;% required a reduced Tinzaparin bolus, and 18&#x000a0;% stopped HD early due to clotting without Tinzaparin. Of those who received anticoagulation with CD, the median dose of Tinzaparin received was 40&#x000a0;% of the standard dose. There was no difference in dialysis adequacy between groups [<xref ref-type="bibr" rid="CR29">29</xref>]. The main limitation of this study is that the two groups were not treated equally; unlike the CD group, no attempt was made to reduce anticoagulation in the AD group [<xref ref-type="bibr" rid="CR29">29</xref>]. Another single-centre, single-blinded, crossover study randomised twenty-five clinically stable maintenance HD patients to receive either AD or CD weekly in an alternating fashion for four weeks [<xref ref-type="bibr" rid="CR28">28</xref>]. The primary outcome was systemic haemodynamics; secondary outcomes were coagulation activation, acid&#x02013;base balance, calcium balance, and dialysis adequacy. Compared with AD, the CD group had significantly lower blood pressure and peripheral vascular resistance without any difference in stroke volume. However, the decrease in SBP was ablated with dialysate calcium supplementation in the last study week. CD resulted in a significant increase in pre-HD bicarbonate levels, lower post-HD ionized calcium, and higher Kt/V without any effect on coagulation parameters [<xref ref-type="bibr" rid="CR28">28</xref>]. This study did not assess the effect of CD on intradialytic heparin dose (heparin was used per usual protocol in both groups); the effect of CD on IDH was also not examined [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p>Four observational studies specifically address heparin use with CD in maintenance HD patients [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. One study included 277 chronic HD patients from eight HD units in an eight-week long, open-label, sequential four-phase study [<xref ref-type="bibr" rid="CR26">26</xref>]. The primary outcome was change in mean effective conductivity clearance with CD (and reduced heparin) versus AD (and standard heparin dose). Each study phase was two weeks long (6 HD sessions). In the first baseline phase, patients received AD and 100&#x000a0;% of their standard heparin dose. In subsequent phases, patients received CD and decreasing amounts of heparin (second phase: CD and 100&#x000a0;% of standard heparin dose; third phase: CD and 80&#x000a0;% of standard heparin dose; fourth phase: CD and 2/3 of standard heparin dose). At the end of the study, there was no difference in dialysis adequacy between baseline (AD with 100&#x000a0;% heparin) and subsequent phases (CD with decreased heparin). Even with a 33&#x000a0;% reduction in heparin, there was no difference in HD circuit clotting, and dialysis adequacy was maintained [<xref ref-type="bibr" rid="CR26">26</xref>]. This study did not assess if a reduced heparin dose was possible with AD [<xref ref-type="bibr" rid="CR26">26</xref>]. In another prospective study, chlorhydric-acid based dialysate was compared with CD in ten patients treated with post-dilution online haemodiafiltration [<xref ref-type="bibr" rid="CR24">24</xref>]. During treatments with CD, the heparin dose was decreased by half, then completely discontinued. In 120 CD sessions without heparin, dialysis adequacy was unchanged, and only one clotting episode related to vascular access stenosis was experienced [<xref ref-type="bibr" rid="CR24">24</xref>]. Two further observational studies, published in abstract form only, included 20 and 31 chronic HD patients, respectively, who had prolonged bleeding from vascular access needling sites post HD. Patients were switched from AD to CD, and intradialytic heparin doses were reduced by 30&#x000a0;% [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] after two months, and 55&#x000a0;% [<xref ref-type="bibr" rid="CR30">30</xref>] after four months, respectively. In both studies, heparin reduction with CD was achieved without decrease in dialysis adequacy [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p>Although existing literature suggests that CD use during chronic HD allows intradialytic heparin reduction without sacrifice of dialysis dose, and without other adverse effects, this has yet to be investigated in a rigorous trial. We have presented in detail the motivation, design and strategy for our randomised controlled trial, including methods of recruitment, randomisation, allocation concealment, dialysis intervention, outcome assessment, and data collection. The study protocol is developed according to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 [<xref ref-type="bibr" rid="CR40">40</xref>]; results will be reported following the Consolidated Standards of Reporting Trials (CONSORT) statement [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p>In summary, our randomised crossover trial of chronic HD patients will determine if CD decreases intradialytic heparin requirements, and its affect on haemodynamic stability and dialysis adequacy. Our study will answer a clinically relevant and important question which has not previously been addressed by a well-designed randomised trial.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HD</term><def><p>Haemodialysis</p></def></def-item><def-item><term>CD</term><def><p>Citrate dialysate</p></def></def-item><def-item><term>CHD</term><def><p>Cumulative heparin dose</p></def></def-item><def-item><term>AD</term><def><p>Acetate dialysate</p></def></def-item><def-item><term>PT</term><def><p>Prothrombin time</p></def></def-item><def-item><term>INR</term><def><p>International normalised ratio</p></def></def-item><def-item><term>aPTT</term><def><p>Activated partial thromboplastin time</p></def></def-item><def-item><term>B2M</term><def><p>Beta-2-microglobulin</p></def></def-item><def-item><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term>FBV</term><def><p>Fibre bundle volume</p></def></def-item><def-item><term>IDH</term><def><p>Intradialytic hypotension</p></def></def-item><def-item><term>SBP</term><def><p>Systolic blood pressure</p></def></def-item><def-item><term>CIs</term><def><p>Confidence intervals</p></def></def-item><def-item><term>IQR</term><def><p>Interquartile range</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>DT participated in the study design, and drafted the protocol manuscript. KL participated in data acquisition, and will participate in data analysis. PR participated in the study design and will perform statistical analysis. RQ participated in the study design. NSD participated in the study design and coordination. JM conceived of the study and participated in its design and coordination. All authors read and approved the final protocol manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was funded by the Division of Nephrology, University of Calgary.</p><sec id="FPar1"><title>Disclosures</title><p>The authors have no financial interests in the information contained in this manuscript.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>KG</given-names></name></person-group><article-title>Essentials of anticoagulation in hemodialysis</article-title><source>Hemodial Int</source><year>2007</year><volume>11</volume><issue>2</issue><fpage>178</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1111/j.1542-4758.2007.00166.x</pub-id><pub-id pub-id-type="pmid">17403168</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JI</given-names></name><name><surname>Winkelmayer</surname><given-names>WC</given-names></name></person-group><article-title>Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis</article-title><source>Am J Kidney Dis</source><year>2012</year><volume>60</volume><issue>3</issue><fpage>473</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2012.03.017</pub-id><pub-id pub-id-type="pmid">22560830</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlak</surname><given-names>K</given-names></name><name><surname>Naumnik</surname><given-names>B</given-names></name><name><surname>Brzosko</surname><given-names>S</given-names></name><name><surname>Pawlak</surname><given-names>D</given-names></name><name><surname>Mysliwiec</surname><given-names>M</given-names></name></person-group><article-title>Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients</article-title><source>Am J Nephrol</source><year>2004</year><volume>24</volume><issue>1</issue><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1159/000076244</pub-id><pub-id pub-id-type="pmid">14726627</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronin</surname><given-names>RE</given-names></name><name><surname>Reilly</surname><given-names>RF</given-names></name></person-group><article-title>Unfractionated heparin for hemodialysis: still the best option</article-title><source>Semin Dial</source><year>2010</year><volume>23</volume><issue>5</issue><fpage>510</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1111/j.1525-139X.2010.00770.x</pub-id><pub-id pub-id-type="pmid">21039876</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>N</given-names></name><name><surname>Opris</surname><given-names>A</given-names></name><name><surname>Faure</surname><given-names>V</given-names></name><name><surname>Lorec-Penet</surname><given-names>AM</given-names></name><name><surname>Portugal</surname><given-names>H</given-names></name><name><surname>Dussol</surname><given-names>B</given-names></name><name><surname>Berland</surname><given-names>Y</given-names></name></person-group><article-title>Pharmacodynamics of unfractionated heparin during and after a hemodialysis session</article-title><source>Am J Kidney Dis</source><year>2008</year><volume>51</volume><issue>5</issue><fpage>789</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2007.12.040</pub-id><pub-id pub-id-type="pmid">18436089</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasse</surname><given-names>H</given-names></name><name><surname>Gillen</surname><given-names>DL</given-names></name><name><surname>Ball</surname><given-names>AM</given-names></name><name><surname>Kestenbaum</surname><given-names>BR</given-names></name><name><surname>Seliger</surname><given-names>SL</given-names></name><name><surname>Sherrard</surname><given-names>D</given-names></name><name><surname>Stehman-Breen</surname><given-names>CO</given-names></name></person-group><article-title>Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients</article-title><source>Kidney Int</source><year>2003</year><volume>64</volume><issue>4</issue><fpage>1455</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00225.x</pub-id><pub-id pub-id-type="pmid">12969166</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chachati</surname><given-names>A</given-names></name><name><surname>Godon</surname><given-names>JP</given-names></name></person-group><article-title>Effect of haemodialysis on upper gastrointestinal tract pathology in patients with chronic renal failure</article-title><source>Nephrol Dial Transplant</source><year>1987</year><volume>1</volume><issue>4</issue><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">3110680</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>TC</given-names></name><name><surname>Montez-Rath</surname><given-names>ME</given-names></name><name><surname>Paik</surname><given-names>J</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Desai</surname><given-names>M</given-names></name><name><surname>Winkelmayer</surname><given-names>WC</given-names></name></person-group><article-title>Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients</article-title><source>J Am Soc Nephrol</source><year>2012</year><volume>23</volume><issue>3</issue><fpage>495</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1681/ASN.2011070658</pub-id><pub-id pub-id-type="pmid">22266666</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seliger</surname><given-names>SL</given-names></name><name><surname>Gillen</surname><given-names>DL</given-names></name><name><surname>Longstreth</surname><given-names>WT</given-names><suffix>Jr</suffix></name><name><surname>Kestenbaum</surname><given-names>B</given-names></name><name><surname>Stehman-Breen</surname><given-names>CO</given-names></name></person-group><article-title>Elevated risk of stroke among patients with end-stage renal disease</article-title><source>Kidney Int</source><year>2003</year><volume>64</volume><issue>2</issue><fpage>603</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00101.x</pub-id><pub-id pub-id-type="pmid">12846756</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>A</given-names></name></person-group><article-title>Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>54</volume><issue>2</issue><fpage>361</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2009.03.012</pub-id><pub-id pub-id-type="pmid">19481318</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasstrom</surname><given-names>B</given-names></name><name><surname>Olivecrona</surname><given-names>G</given-names></name><name><surname>Olivecrona</surname><given-names>T</given-names></name><name><surname>Stegmayr</surname><given-names>BG</given-names></name></person-group><article-title>Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients</article-title><source>Scand J Clin Lab Invest</source><year>2003</year><volume>63</volume><issue>1</issue><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1080/00365510310000484</pub-id><pub-id pub-id-type="pmid">12729069</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulman</surname><given-names>S</given-names></name><name><surname>Hellgren-Wangdahl</surname><given-names>M</given-names></name></person-group><article-title>Pregnancy, heparin and osteoporosis</article-title><source>Thromb Haemost</source><year>2002</year><volume>87</volume><issue>2</issue><fpage>180</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">11858474</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binici</surname><given-names>DN</given-names></name><name><surname>Gunes</surname><given-names>N</given-names></name></person-group><article-title>Risk factors leading to reduced bone mineral density in hemodialysis patients with metabolic syndrome</article-title><source>Ren Fail</source><year>2010</year><volume>32</volume><issue>4</issue><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.3109/08860221003675260</pub-id><pub-id pub-id-type="pmid">20446786</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>KN</given-names></name><name><surname>Ho</surname><given-names>K</given-names></name><name><surname>Cheung</surname><given-names>RC</given-names></name><name><surname>Lit</surname><given-names>LC</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Fung</surname><given-names>KS</given-names></name><name><surname>Tong</surname><given-names>MK</given-names></name><name><surname>Lam</surname><given-names>CW</given-names></name></person-group><article-title>Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis</article-title><source>Int J Artif Organs</source><year>2001</year><volume>24</volume><issue>7</issue><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">11510916</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edes</surname><given-names>TE</given-names></name></person-group><article-title>Heparin-induced hyperkalemia</article-title><source>Postgrad Med</source><year>1990</year><volume>87</volume><issue>4</issue><fpage>104</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">2315239</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hottelart</surname><given-names>C</given-names></name><name><surname>Achard</surname><given-names>JM</given-names></name><name><surname>Moriniere</surname><given-names>P</given-names></name><name><surname>Zoghbi</surname><given-names>F</given-names></name><name><surname>Dieval</surname><given-names>J</given-names></name><name><surname>Fournier</surname><given-names>A</given-names></name></person-group><article-title>Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin</article-title><source>Artif Organs</source><year>1998</year><volume>22</volume><issue>7</issue><fpage>614</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1594.1998.06204.x</pub-id><pub-id pub-id-type="pmid">9684701</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>A</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name></person-group><article-title>Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients</article-title><source>Dial Transplant</source><year>2000</year><volume>29</volume><fpage>620</fpage><lpage>626</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Callan</surname><given-names>R</given-names></name><name><surname>Cole</surname><given-names>JJ</given-names></name><name><surname>Blagg</surname><given-names>CR</given-names></name></person-group><article-title>Dialysate made from dry chemicals using citric acid increases dialysis dose</article-title><source>Am J Kidney Dis</source><year>2000</year><volume>35</volume><issue>3</issue><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(00)70203-4</pub-id><pub-id pub-id-type="pmid">10692276</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Callan</surname><given-names>R</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><name><surname>Blagg</surname><given-names>C</given-names></name></person-group><article-title>Increased dialyzer reuse with citrate dialysate</article-title><source>Hemodial Int</source><year>2005</year><volume>9</volume><issue>3</issue><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1111/j.1492-7535.2005.01140.x</pub-id><pub-id pub-id-type="pmid">16191076</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kossmann</surname><given-names>RJ</given-names></name><name><surname>Gonzales</surname><given-names>A</given-names></name><name><surname>Callan</surname><given-names>R</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name></person-group><article-title>Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study</article-title><source>Clin J Am Soc Nephrol</source><year>2009</year><volume>4</volume><issue>9</issue><fpage>1459</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.2215/CJN.02590409</pub-id><pub-id pub-id-type="pmid">19661218</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daimon</surname><given-names>S</given-names></name><name><surname>Dan</surname><given-names>K</given-names></name><name><surname>Kawano</surname><given-names>M</given-names></name></person-group><article-title>Comparison of acetate-free citrate hemodialysis and bicarbonate hemodialysis regarding the effect of intra-dialysis hypotension and post-dialysis malaise</article-title><source>Ther Apher Dial</source><year>2011</year><volume>15</volume><issue>5</issue><fpage>460</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1111/j.1744-9987.2011.00976.x</pub-id><pub-id pub-id-type="pmid">21974699</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuragano</surname><given-names>T</given-names></name><name><surname>Kida</surname><given-names>A</given-names></name><name><surname>Furuta</surname><given-names>M</given-names></name><name><surname>Yahiro</surname><given-names>M</given-names></name><name><surname>Kitamura</surname><given-names>R</given-names></name><name><surname>Otaki</surname><given-names>Y</given-names></name><name><surname>Nonoguchi</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name></person-group><article-title>Effects of acetate-free citrate-containing dialysate on metabolic acidosis, anemia, and malnutrition in hemodialysis patients</article-title><source>Artif Organs</source><year>2012</year><volume>36</volume><issue>3</issue><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1111/j.1525-1594.2011.01349.x</pub-id><pub-id pub-id-type="pmid">21954915</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuragano</surname><given-names>T</given-names></name><name><surname>Furuta</surname><given-names>M</given-names></name><name><surname>Yahiro</surname><given-names>M</given-names></name><name><surname>Kida</surname><given-names>A</given-names></name><name><surname>Otaki</surname><given-names>Y</given-names></name><name><surname>Hasuike</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name></person-group><article-title>Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patients with low intact-PTH</article-title><source>BMC Nephrol</source><year>2013</year><volume>14</volume><fpage>18-2369</fpage><lpage>14-18</lpage><pub-id pub-id-type="doi">10.1186/1471-2369-14-18</pub-id><pub-id pub-id-type="pmid">23327614</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aniort</surname><given-names>J</given-names></name><name><surname>Petitclerc</surname><given-names>T</given-names></name><name><surname>Creput</surname><given-names>C</given-names></name></person-group><article-title>Safe use of citric acid-based dialysate and heparin removal in postdilution online hemodiafiltration</article-title><source>Blood Purif</source><year>2012</year><volume>34</volume><issue>3&#x02013;4</issue><fpage>336</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1159/000345342</pub-id><pub-id pub-id-type="pmid">23306782</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>A</given-names></name><name><surname>Hagiwara</surname><given-names>S</given-names></name><name><surname>Tanimoto</surname><given-names>M</given-names></name><name><surname>Kodama</surname><given-names>F</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Nohara</surname><given-names>N</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Maiguma</surname><given-names>M</given-names></name><name><surname>Omote</surname><given-names>K</given-names></name><name><surname>Io</surname><given-names>H</given-names></name><name><surname>Kurusu</surname><given-names>A</given-names></name><name><surname>Ohsawa</surname><given-names>I</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Hamada</surname><given-names>C</given-names></name><name><surname>Horikoshi</surname><given-names>S</given-names></name><name><surname>Tomino</surname><given-names>Y</given-names></name></person-group><article-title>Effects of acetate-free citrate dialysate on glycoxidation and lipid peroxidation products in hemodialysis patients</article-title><source>Nephron Extra</source><year>2012</year><volume>2</volume><issue>1</issue><fpage>256</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1159/000342258</pub-id><pub-id pub-id-type="pmid">23599704</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sands</surname><given-names>JJ</given-names></name><name><surname>Kotanko</surname><given-names>P</given-names></name><name><surname>Segal</surname><given-names>JH</given-names></name><name><surname>Ho</surname><given-names>CH</given-names></name><name><surname>Usvat</surname><given-names>L</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Carter</surname><given-names>M</given-names></name><name><surname>Sergeyeva</surname><given-names>O</given-names></name><name><surname>Korth</surname><given-names>L</given-names></name><name><surname>Maunsell</surname><given-names>E</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Krishnan</surname><given-names>M</given-names></name><name><surname>Diaz-Buxo</surname><given-names>JA</given-names></name></person-group><article-title>Effects of citrate acid concentrate (citrasate(R)) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial</article-title><source>Blood Purif</source><year>2012</year><volume>33</volume><issue>1&#x02013;3</issue><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1159/000334157</pub-id><pub-id pub-id-type="pmid">22269855</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panichi</surname><given-names>V</given-names></name><name><surname>Fiaccadori</surname><given-names>E</given-names></name><name><surname>Rosati</surname><given-names>A</given-names></name><name><surname>Fanelli</surname><given-names>R</given-names></name><name><surname>Bernabini</surname><given-names>G</given-names></name><name><surname>Scatena</surname><given-names>A</given-names></name><name><surname>Pizzarelli</surname><given-names>F</given-names></name></person-group><article-title>Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients</article-title><source>ScientificWorld J</source><year>2013</year><volume>2013</volume><fpage>703612</fpage><pub-id pub-id-type="doi">10.1155/2013/703612</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabutti</surname><given-names>L</given-names></name><name><surname>Lucchini</surname><given-names>B</given-names></name><name><surname>Marone</surname><given-names>C</given-names></name><name><surname>Alberio</surname><given-names>L</given-names></name><name><surname>Burnier</surname><given-names>M</given-names></name></person-group><article-title>Citrate- vs. acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid&#x02013;base status, and electrolytes</article-title><source>BMC Nephrol</source><year>2009</year><volume>10</volume><fpage>7-2369</fpage><lpage>10-7</lpage><pub-id pub-id-type="doi">10.1186/1471-2369-10-7</pub-id><pub-id pub-id-type="pmid">19265544</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegmayr</surname><given-names>BG</given-names></name><name><surname>Jonsson</surname><given-names>P</given-names></name><name><surname>Mahmood</surname><given-names>D</given-names></name></person-group><article-title>A significant proportion of patients treated with citrate containing dialysate need additional anticoagulation</article-title><source>Int J Artif Organs</source><year>2013</year><volume>36</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.5301/ijao.5000172</pub-id><pub-id pub-id-type="pmid">23280073</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Kossman RJ, Callan R, Ahmad S. Fifty-five percent heparin reduction is sate with citrate dialysate in chronic dialysis patients [abstract]. American Society of Nephrology Annual Meeting 2006</mixed-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>O</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>C</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Yamagata</surname><given-names>T</given-names></name><name><surname>Muto</surname><given-names>S</given-names></name><name><surname>Momoi</surname><given-names>M</given-names></name><name><surname>Kusano</surname><given-names>E</given-names></name></person-group><article-title>Metabolic and hemodynamic advantages of an acetate-free citrate dialysate in a uremic case of congenital methylmalonic acidemia</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>54</volume><issue>4</issue><fpage>764</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2009.04.033</pub-id><pub-id pub-id-type="pmid">19577350</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanevold</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Yonekawa</surname><given-names>K</given-names></name></person-group><article-title>Utility of citrate dialysate in management of acute kidney injury in children</article-title><source>Hemodial Int</source><year>2010</year><volume>14</volume><issue>Suppl 1</issue><fpage>S2</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1542-4758.2010.00483.x</pub-id><pub-id pub-id-type="pmid">21040414</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winrow</surname><given-names>RM</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Halldorson</surname><given-names>JB</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name></person-group><article-title>Intraoperative dialysis during liver transplantation with citrate dialysate</article-title><source>Hemodial Int</source><year>2009</year><volume>13</volume><issue>3</issue><fpage>257</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1111/j.1542-4758.2009.00370.x</pub-id><pub-id pub-id-type="pmid">19515070</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagedal</surname><given-names>S</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Osnes</surname><given-names>K</given-names></name><name><surname>Bjornsen</surname><given-names>S</given-names></name><name><surname>Torremocha</surname><given-names>J</given-names></name><name><surname>Fauchald</surname><given-names>P</given-names></name><name><surname>Kofstad</surname><given-names>J</given-names></name><name><surname>Brosstad</surname><given-names>F</given-names></name></person-group><article-title>Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><issue>2</issue><fpage>444</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfi203</pub-id><pub-id pub-id-type="pmid">16234293</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krivitski</surname><given-names>NM</given-names></name><name><surname>Kislukhin</surname><given-names>VV</given-names></name><name><surname>Snyder</surname><given-names>JW</given-names></name><name><surname>MacGibbon</surname><given-names>DR</given-names></name><name><surname>Kuznetsova</surname><given-names>OA</given-names></name><name><surname>Reasons</surname><given-names>AM</given-names></name><name><surname>Depner</surname><given-names>TA</given-names></name></person-group><article-title>In vivo measurement of hemodialyzer fiber bundle volume: theory and validation</article-title><source>Kidney Int</source><year>1998</year><volume>54</volume><issue>5</issue><fpage>1751</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.1998.00146.x</pub-id><pub-id pub-id-type="pmid">9844155</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>BJ</given-names></name><name><surname>Mortis</surname><given-names>GP</given-names></name><name><surname>Taub</surname><given-names>KJ</given-names></name><name><surname>McLaughlin</surname><given-names>K</given-names></name><name><surname>Donaldson</surname><given-names>C</given-names></name><name><surname>Ghali</surname><given-names>WA</given-names></name></person-group><article-title>The Southern Alberta Renal Program database: a prototype for patient management and research initiatives</article-title><source>Clin Invest Med</source><year>2001</year><volume>24</volume><issue>4</issue><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">11558850</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petitclerc</surname><given-names>T</given-names></name><name><surname>Goux</surname><given-names>N</given-names></name><name><surname>Reynier</surname><given-names>AL</given-names></name><name><surname>Bene</surname><given-names>B</given-names></name></person-group><article-title>A model for non-invasive estimation of in vivo dialyzer performances and patient&#x02019;s conductivity during hemodialysis</article-title><source>Int J Artif Organs</source><year>1993</year><volume>16</volume><issue>8</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">8225649</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhlmann</surname><given-names>U</given-names></name><name><surname>Goldau</surname><given-names>R</given-names></name><name><surname>Samadi</surname><given-names>N</given-names></name><name><surname>Graf</surname><given-names>T</given-names></name><name><surname>Gross</surname><given-names>M</given-names></name><name><surname>Orlandini</surname><given-names>G</given-names></name><name><surname>Lange</surname><given-names>H</given-names></name></person-group><article-title>Accuracy and safety of online clearance monitoring based on conductivity variation</article-title><source>Nephrol Dial Transplant</source><year>2001</year><volume>16</volume><issue>5</issue><fpage>1053</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1093/ndt/16.5.1053</pub-id><pub-id pub-id-type="pmid">11328916</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Ahmad S, Callan R, Kossman R. Heparin reduction with citrate dialysate [abstract]. Nephrol Dial Transplant 2006; 21:suppl.4.</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Dickersin</surname><given-names>K</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group><article-title>SPIRIT 2013: new guidance for content of clinical trial protocols</article-title><source>Lancet</source><year>2013</year><volume>381</volume><issue>9861</issue><fpage>91</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)62160-6</pub-id><pub-id pub-id-type="pmid">23305999</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><collab>CONSORT Group</collab></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title><source>Int J Surg</source><year>2011</year><volume>9</volume><issue>8</issue><fpage>672</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2011.09.004</pub-id><pub-id pub-id-type="pmid">22019563</pub-id></element-citation></ref></ref-list></back></article>